Insider Buying: Neonc Technologies (NASDAQ:NTHI) CEO Purchases $59,400.00 in Stock

Posted by on Sep 15th, 2026

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Amir Heshmatpour bought 15,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average price of $3.96 per share, for a total transaction of $59,400.00. Following the acquisition, the chief executive officer owned 3,148,000 shares of the company’s stock, valued at $12,466,080. This trade represents a 0.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Neonc Technologies Stock Performance

NTHI traded down $0.47 during trading on Tuesday, reaching $3.31. 285,988 shares of the stock traded hands, compared to its average volume of 104,731. The stock’s 50-day moving average is $4.04 and its 200 day moving average is $5.27. Neonc Technologies Holdings, Inc. has a 12 month low of $3.01 and a 12 month high of $12.99.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. BTIG Research reiterated a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, September 8th. Wall Street Zen downgraded shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Alliance Global Partners initiated coverage on shares of Neonc Technologies in a research report on Tuesday, May 19th. They set a “buy” rating and a $13.00 target price for the company. Finally, Maxim Group started coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They issued a “buy” rating and a $20.00 target price for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Neonc Technologies has an average rating of “Hold” and an average price target of $16.00.

Read Our Latest Report on NTHI

Institutional Trading of Neonc Technologies

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Neonc Technologies by 5.0% in the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after purchasing an additional 11,108 shares during the last quarter. Westmount Partners LLC grew its stake in Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after purchasing an additional 153,858 shares during the period. BlackRock Inc. purchased a new stake in shares of Neonc Technologies during the 2nd quarter valued at $815,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Neonc Technologies during the 2nd quarter worth $126,000.

Key Headlines Impacting Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

  • Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
  • Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
  • Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
  • Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
  • Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

About Neonc Technologies

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Read More

Insider Buying and Selling by Quarter for Neonc Technologies (NASDAQ:NTHI)

Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.